TherapeuticsMD Inc (TXMD) Stake Lessened by Teacher Retirement System of Texas

Share on StockTwits

Teacher Retirement System of Texas cut its stake in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 33.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,372 shares of the company’s stock after selling 19,628 shares during the period. Teacher Retirement System of Texas’ holdings in TherapeuticsMD were worth $187,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. MANA Advisors LLC acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth $104,000. Paloma Partners Management Co acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth $105,000. Trellus Management Company LLC acquired a new stake in shares of TherapeuticsMD during the first quarter worth $317,000. MetLife Investment Advisors LLC acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth $423,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of TherapeuticsMD during the first quarter worth $455,000. 72.70% of the stock is currently owned by institutional investors.

Shares of TherapeuticsMD opened at $6.99 on Wednesday, MarketBeat.com reports. TherapeuticsMD Inc has a 1-year low of $4.34 and a 1-year high of $7.66. The firm has a market cap of $1.52 billion, a PE ratio of -18.89 and a beta of 1.34.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Thursday, May 3rd. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). TherapeuticsMD had a negative net margin of 483.98% and a negative return on equity of 66.77%. The business had revenue of $3.77 million for the quarter, compared to analysts’ expectations of $4.18 million. During the same quarter in the prior year, the firm posted ($0.11) EPS. The business’s quarterly revenue was down 5.4% compared to the same quarter last year. analysts expect that TherapeuticsMD Inc will post -0.51 EPS for the current fiscal year.

TXMD has been the topic of a number of recent analyst reports. ValuEngine raised TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Monday, April 2nd. Oppenheimer reaffirmed a “buy” rating on shares of TherapeuticsMD in a research report on Wednesday, March 21st. Zacks Investment Research lowered TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Wednesday, April 25th. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a report on Friday, March 9th. Finally, JPMorgan Chase & Co. started coverage on TherapeuticsMD in a report on Friday, June 15th. They set an “overweight” rating and a $11.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. TherapeuticsMD presently has a consensus rating of “Buy” and an average price target of $14.63.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand
Yankees Former Ace Ron Guidry Says Luis Severino Will Break His Records
Yankees Former Ace Ron Guidry Says Luis Severino Will Break His Records
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season


Leave a Reply

 
© 2006-2018 BBNS.